447 related articles for article (PubMed ID: 16778214)
1. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Gore SD; Baylin S; Sugar E; Carraway H; Miller CB; Carducci M; Grever M; Galm O; Dauses T; Karp JE; Rudek MA; Zhao M; Smith BD; Manning J; Jiemjit A; Dover G; Mays A; Zwiebel J; Murgo A; Weng LJ; Herman JG
Cancer Res; 2006 Jun; 66(12):6361-9. PubMed ID: 16778214
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
Leone G; Voso MT; Teofili L; Lübbert M
Clin Immunol; 2003 Oct; 109(1):89-102. PubMed ID: 14585280
[TBL] [Abstract][Full Text] [Related]
3. Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines.
Fialova B; Smesny Trtkova K; Paskova L; Langova K; Kolar Z
Oncol Rep; 2013 May; 29(5):2039-45. PubMed ID: 23503510
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.
Egger G; Aparicio AM; Escobar SG; Jones PA
Cancer Res; 2007 Jan; 67(1):346-53. PubMed ID: 17210717
[TBL] [Abstract][Full Text] [Related]
5. Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression.
Scott SA; Lakshimikuttysamma A; Sheridan DP; Sanche SE; Geyer CR; DeCoteau JF
Exp Hematol; 2007 Feb; 35(2):263-73. PubMed ID: 17258075
[TBL] [Abstract][Full Text] [Related]
6. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.
Maslak P; Chanel S; Camacho LH; Soignet S; Pandolfi PP; Guernah I; Warrell R; Nimer S
Leukemia; 2006 Feb; 20(2):212-7. PubMed ID: 16357841
[TBL] [Abstract][Full Text] [Related]
7. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
Goodyear O; Agathanggelou A; Novitzky-Basso I; Siddique S; McSkeane T; Ryan G; Vyas P; Cavenagh J; Stankovic T; Moss P; Craddock C
Blood; 2010 Sep; 116(11):1908-18. PubMed ID: 20530795
[TBL] [Abstract][Full Text] [Related]
8. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
[TBL] [Abstract][Full Text] [Related]
9. DNA methyltransferases as targets for cancer therapy.
Ghoshal K; Bai S
Drugs Today (Barc); 2007 Jun; 43(6):395-422. PubMed ID: 17612710
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic changes in the myelodysplastic syndrome.
Issa JP
Hematol Oncol Clin North Am; 2010 Apr; 24(2):317-30. PubMed ID: 20359628
[TBL] [Abstract][Full Text] [Related]
11. [Expression of neprilysin gene is associated with methylation and histone modification on promoter in mouse neuroblastoma Neuro-2a cells].
Deng Y; Lu X; Liu L; Li T; Zhang Y; Guo X; Yu G
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Aug; 30(8):810-3. PubMed ID: 25108432
[TBL] [Abstract][Full Text] [Related]
12. Current status of epigenetic treatment in myelodysplastic syndromes.
Kuendgen A; Lübbert M
Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia cells.
Laurenzana A; Petruccelli LA; Pettersson F; Figueroa ME; Melnick A; Baldwin AS; Paoletti F; Miller WH
Cancer Res; 2009 Jan; 69(1):55-64. PubMed ID: 19117987
[TBL] [Abstract][Full Text] [Related]
14. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
Figueroa ME; Skrabanek L; Li Y; Jiemjit A; Fandy TE; Paietta E; Fernandez H; Tallman MS; Greally JM; Carraway H; Licht JD; Gore SD; Melnick A
Blood; 2009 Oct; 114(16):3448-58. PubMed ID: 19652201
[TBL] [Abstract][Full Text] [Related]
15. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Garcia-Manero G; Kantarjian HM; Sanchez-Gonzalez B; Yang H; Rosner G; Verstovsek S; Rytting M; Wierda WG; Ravandi F; Koller C; Xiao L; Faderl S; Estrov Z; Cortes J; O'brien S; Estey E; Bueso-Ramos C; Fiorentino J; Jabbour E; Issa JP
Blood; 2006 Nov; 108(10):3271-9. PubMed ID: 16882711
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Giles F; Fischer T; Cortes J; Garcia-Manero G; Beck J; Ravandi F; Masson E; Rae P; Laird G; Sharma S; Kantarjian H; Dugan M; Albitar M; Bhalla K
Clin Cancer Res; 2006 Aug; 12(15):4628-35. PubMed ID: 16899611
[TBL] [Abstract][Full Text] [Related]
17. DNA methyltransferase inhibitor RG108 and histone deacetylase inhibitors cooperate to enhance NB4 cell differentiation and E-cadherin re-expression by chromatin remodelling.
Savickiene J; Treigyte G; Jazdauskaite A; Borutinskaite VV; Navakauskiene R
Cell Biol Int; 2012 Nov; 36(11):1067-78. PubMed ID: 22845560
[TBL] [Abstract][Full Text] [Related]
18. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Griffiths EA; Gore SD
Semin Hematol; 2008 Jan; 45(1):23-30. PubMed ID: 18179966
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
20. Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.
Lübbert M; Kuendgen A
Cancer; 2015 Feb; 121(4):498-501. PubMed ID: 25336205
[No Abstract] [Full Text] [Related]
[Next] [New Search]
